Filgrastim
- Generic Name
- Filgrastim
- Brand Names
- Accofil, Granix, Grastofil, Neupogen, Nivestim, Nivestym, Ratiograstim, Releuko, Zarxio, Zarzio, Filgrastim Hexal, Tevagrastim
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 121181-53-1
- Unique Ingredient Identifier
- PVI5M0M1GW
- Background
Filgrastim is a short-acting recombinant, non-pegylated human granulocyte colony-stimulating factor (G-CSF) analog produced by recombinant DNA technology. It has an amino acid sequence identical to endogenous G-CSF, but it is non-glycosylated unlike the endogenous G-CSF and has an N-terminal methionine added in the sequence for expression in E. Coli. Human G...
- Indication
Filgrastim is indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever.
...
- Associated Conditions
- Congenital neutropenia, Cyclic neutropenia, Febrile Neutropenia, Hematopoietic Subsyndrome of Acute Radiation Syndrome, Idiopathic neutropenia, Infection, Neutropenia
- Associated Therapies
- Mobilization of hematopoietic progenitor cells into peripheral blood for collection by leukapheresis therapy
Cardiac Safe Transplants for Systemic Sclerosis
- First Posted Date
- 2018-07-20
- Last Posted Date
- 2020-08-12
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 9
- Registration Number
- NCT03593902
- Locations
- 🇺🇸
Northwestern University, Feinberg School of Medicine, Chicago, Illinois, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders
- Conditions
- Interventions
- First Posted Date
- 2018-07-09
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 48
- Registration Number
- NCT03579875
- Locations
- 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
Autologous Bone Marrow Stem Cell Ovarian Transplantation to Restore Ovarian Function in Premature Ovarian Failure
- First Posted Date
- 2018-05-24
- Last Posted Date
- 2018-05-24
- Lead Sponsor
- Instituto de Investigacion Sanitaria La Fe
- Target Recruit Count
- 20
- Registration Number
- NCT03535480
- Locations
- 🇪🇸
Hospital Universitario y Politécnico la Fe-IIS la Fe, Valencia, Spain
Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure
- First Posted Date
- 2018-04-18
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- Paul Szabolcs
- Target Recruit Count
- 8
- Registration Number
- NCT03500731
- Locations
- 🇺🇸
UPMC Presbyterian, Pittsburgh, Pennsylvania, United States
🇺🇸Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression
- Conditions
- Interventions
- First Posted Date
- 2018-03-29
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Dartmouth-Hitchcock Medical Center
- Target Recruit Count
- 21
- Registration Number
- NCT03480360
- Locations
- 🇺🇸
Dartmouth Hitchcock Medical Center, Norris Cotton Cancer Center, Lebanon, New Hampshire, United States
Lintuzumab-Ac225 in Combination with Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2018-02-22
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- Medical College of Wisconsin
- Target Recruit Count
- 26
- Registration Number
- NCT03441048
- Locations
- 🇺🇸
Froedtert Hospital and the Medical College of Wisconsin, Milwuakee, Wisconsin, United States
Chemotherapy and G-CSF for Mobilization
- Conditions
- Interventions
- First Posted Date
- 2018-02-22
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- Insel Gruppe AG, University Hospital Bern
- Target Recruit Count
- 137
- Registration Number
- NCT03442673
- Locations
- 🇨🇭
Department for Medical Oncology University Hospital/Inselspital, Berne, Switzerland
Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation
- Conditions
- Interventions
- First Posted Date
- 2018-02-15
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 46
- Registration Number
- NCT03434730
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
G-CSF in Decompensated Cirrhosis: an Open Label Trial
- First Posted Date
- 2018-01-30
- Last Posted Date
- 2018-01-30
- Target Recruit Count
- 100
- Registration Number
- NCT03415698
- Locations
- 🇮🇳
Post Graduate Institute of Medical Education and Research, Chandigarh, India
DLAAG in the Treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome With Blast Excess
- Conditions
- Interventions
- First Posted Date
- 2017-11-29
- Last Posted Date
- 2017-11-29
- Lead Sponsor
- Shanghai Tong Ren Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT03356080
- Locations
- 🇨🇳
The center hospital of Shanghai Fengxian District, Shanghai, China
🇨🇳Fujian Medical University Union Hospital, Fuzhou, China
🇨🇳First Affiliated Hospital of Zhengzhou University., Zhengzhou, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.